<strong></strong>Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

Bone marrow-derived mesenchymal stem cells (BMSCs) have been considered a promising therapeutic approach to cardiovascular disease. This study intends to compare the effect of BMSCs through a standard active cardiac support device (ASD) and intravenous injection on global myocardial injury induced by isoproterenol. BMSCs were cultured in vitro, and the transplanted cells were labeled with a fluorescent dye CM-Dil. Isoproterenol (ISO) was injected into the rats; two weeks later, the labeled cells were transplanted into ISO-induced heart-injury rats through the tail vein or ASD device for five days. The rats were sacrificed on the first day, the third day, and the fifth day after transplantation to observe the distribution of cells in the myocardium by fluorescence microscopy. The hemodynamic indexes of the left ventricle were measured before sacrificing. H&E staining and Masson’s trichrome staining were used to evaluate the cardiac histopathology. In the ASD groups, after three days of transplantation, there were many BMSCs on the epicardial surface, and after five days of transplantation, BMSCs were widely distributed in the ventricular muscle. But in the intravenous injection group, there were no labeled-BMSCs distributed. In the ASD+BMSCs-three days treated group and ASD+BMSCs -five days-treated group, left ventricular systolic pressure (LVSP), the maximum rate of left ventricular pressure rise (+dP/dt), the maximum rate of left ventricular pressure decline (-dP/dt) increased compared with model group and intravenous injection group (P<0.05). By giving BMSCs through ASD device, cells can rapidly and widely distribute in the myocardium and significantly improve heart function.

Download Full-text

Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

10.20944/preprints202004.0227.v2 ◽

2020 ◽

Cited By ~ 1

Author(s):

Ziwei Liu ◽

Muhammad Naveed ◽

Mirza Muhammad Faran Ashraf Baig ◽

Reyaj Mikrani ◽

Cuican Li ◽

...

Keyword(s):

Stem Cells ◽

Bone Marrow ◽

Intravenous Injection ◽

Maximum Rate ◽

Myocardial Injury ◽

Left Ventricular Pressure ◽

Treated Group ◽

Left Ventricular ◽

Support Device ◽

Cardiac Support Device

Bone marrow-derived mesenchymal stem cells (BMSCs) have been considered a promising therapeutic approach to cardiovascular disease. This study intends to compare the effect of BMSCs through a standard active cardiac support device (ASD) and intravenous injection on global myocardial injury induced by isoproterenol. BMSCs were cultured in vitro, and the transplanted cells were labeled with a fluorescent dye CM-Dil. Isoproterenol (ISO) was injected into the rats; two weeks later, the labeled cells were transplanted into ISO-induced heart injury rats through the tail vein and ASD device for five days. The rats were sacrificed on the first day, the third day, and the fifth day after transplantation to observe the distribution of cells in the myocardium by fluorescence microscopy. The hemodynamic indexes of the left ventricle were measured before sacrificing. H&E staining and Masson’s trichrome staining were used to evaluate the cardiac histopathology. In the ASD groups, after three days of transplantation, there were a large number of BMSCs on the epicardial surface, and after five days of transplantation, BMSCs were widely distributed in the ventricular muscle. But in the intravenous injection group, there were no labeled-BMSCs distributed. In the ASD+BMSCs-three days treated group and ASD+BMSCs -five days-treated group, left ventricular systolic pressure (LVSP), maximum rate of left ventricular pressure rise (+dP/dt), maximum rate of left ventricular pressure decline (-dP/dt) increased compared with model group and intravenous injection group (P<0.05). By giving BMSCs through ASD device, cells can rapidly and widely are distributed in the myocardium and significantly improve heart function.

Download Full-text

Therapeutic approach for global myocardial injury using bone marrow-derived mesenchymal stem cells by cardiac support device in rats

Biomedical Microdevices ◽

10.1007/s10544-020-00538-9 ◽

2021 ◽

Vol 23 (1) ◽

Author(s):

Ziwei Liu ◽

Muhammad Naveed ◽

Mirza Muhammad Faran Ashraf Baig ◽

Reyaj Mikrani ◽

Cuican Li ◽

...

Keyword(s):

Stem Cells ◽

Bone Marrow ◽

Mesenchymal Stem Cells ◽

Therapeutic Approach ◽

Myocardial Injury ◽

Support Device ◽

Cardiac Support Device

Download Full-text

CD51 distinguishes a subpopulation of bone marrow mesenchymal stem cells with distinct migratory potential: a novel cell-based strategy to treat acute myocardial infarction in mice

Stem Cell Research & Therapy ◽

10.1186/s13287-019-1439-y ◽

2019 ◽

Vol 10 (1) ◽

Author(s):

Dong-Mei Xie ◽

Yuan-Long Li ◽

Jie Li ◽

Qinglang Li ◽

Guihua Lu ◽

...

Keyword(s):

Myocardial Infarction ◽

Stem Cells ◽

Bone Marrow ◽

Intravenous Injection ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

Differentiation Potential ◽

Migratory Capacity

Abstract Background Experimental and clinical trials have demonstrated the efficiency of bone marrow-derived mesenchymal stromal/stem cells (bMSCs) in the treatment of myocardial infarction. However, after intravenous injection, the ineffective migration of engrafted bMSCs to the hearts remains an obstacle, which has an undesirable impact on the efficiency of cell-based therapy. Therefore, we attempted to identify a marker that could distinguish a subpopulation of bMSCs with a promising migratory capacity. Methods Here, CD51-negative and CD51-positive cells were isolated by flow cytometry from Ter119−CD45−CD31−bMSCs and cultured in specifically modified medium. The proliferation ability of the cells was evaluated by 5-ethynyl-2′-deoxyuridine (EdU) staining or continuously monitored during culture, and the differentiation potential was assessed by culturing the cells in the appropriate conditioned media. Wound healing assays, transwell assays and quantitative polymerase chain reaction (qPCR) were used to measure the migratory ability. The mice were subjected to a sham operation or myocardial infarction (MI) by permanently occluding the coronary artery, and green fluorescent protein (GFP)-labelled cells were transplanted into the mice via intravenous infusion immediately after MI. Heart function was measured by echocardiography; infarct myocardium tissues were detected by triphenyl tetrazolium chloride (TTC) staining. Additionally, immunofluorescence staining was used to verify the characteristics of CD51+bMSCs and inflammatory responses in vivo. Statistical comparisons were performed using a two-tailed Student’s t test. Results In this study, the isolated CD51−bMSCs and CD51+bMSCs, especially the CD51+ cells, presented a favourable proliferative capacity and could differentiate into adipocytes, osteocytes and chondrocytes in vitro. After the cells were transplanted into the MI mice by intravenous injection, the therapeutic efficiency of CD51+bMSCs in improving left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) was better than that of CD51−bMSCs. Compared with CD51−bMSCs, CD51+bMSCs preferentially migrated to and were retained in the infarcted hearts at 48 h and 8 days after intravenous injection. Accordingly, the migratory capacity of CD51+bMSCs exceeded that of CD51−bMSCs in vitro, and the former cells expressed higher levels of chemokine receptors or ligands. Interestingly, the retained CD51+bMSCs retained in the myocardium possessed proliferative potential but only differentiated into endothelial cells, smooth muscle cells, fibroblasts or cardiomyocytes. Transplantation of CD51+bMSCs partially attenuated the inflammatory response in the hearts after MI, while the potential for inflammatory suppression was low in CD51−bMSC-treated mice. Conclusions These findings indicated that the CD51-distinguished subpopulation of bMSCs facilitated proliferation and migration both in vitro and in vivo, which provided a novel cell-based strategy to treat acute MI in mice by intravenous injection.

Download Full-text

Cardiac support device (ASD) delivers bone marrow stem cells repetitively to epicardium has promising curative effects in advanced heart failure

Biomedical Microdevices ◽

10.1007/s10544-018-0282-8 ◽

2018 ◽

Vol 20 (2) ◽

Cited By ~ 9

Author(s):

Shizhong Yue ◽

Muhammad Naveed ◽

Wang Gang ◽

Dingding Chen ◽

Zhijie Wang ◽

...

Keyword(s):

Heart Failure ◽

Stem Cells ◽

Bone Marrow ◽

Advanced Heart Failure ◽

Bone Marrow Stem Cells ◽

Support Device ◽

Cardiac Support Device

Download Full-text

A New Method of Mechanical Circulatory Support with an Implantable Multichamber Pump System (IMPS): Presentation and First Experimental Results

The International Journal of Artificial Organs ◽

10.1177/039139889802100408 ◽

1998 ◽

Vol 21 (4) ◽

pp. 216-224 ◽

Cited By ~ 2

Author(s):

T. Petzold ◽

P. Feindv ◽

V. Paul ◽

E. Gams ◽

K. Gersonde

Keyword(s):

Ventricular Fibrillation ◽

Cardiac Failure ◽

Left Ventricular Pressure ◽

Left Ventricular ◽

Circulatory Support ◽

Pump System ◽

Support Device ◽

The Common ◽

Cardiac Support Device ◽

Pneumatic Pump

This paper presents a new cardiac support device for left ventricular failure which consists of two inflatable bellows positioned dorsally and ventrally to the left ventricle. The implantable multichamber pump system (IMPS) is driven by a pneumatic pump system and controlled by a microcomputer using ECG-trigger and pacemaker modules. It was implanted via thoracotomy in 8 pigs. The circulatory parameters were measured in the animals on β-blockers, with cardiac failure and in ventricular fibrillation with an activated (IMPS on) and deactivated (IMPS off) system. IMPS significantly increased the left ventricular pressure (LVPsys IMPS off: 63 ∓ 6 mmHg vs IMPS on: 96 ∓ 8 mmHg) and the blood pressure in the common carotid artery (Bpca' IMPS off: 69/38 mmHg vs IMPS on: 95/40 mmHg). The IMPS proved to be highly efficient in the therapy of animals with acute cardiac failure and in ventricular fibrillation in the experimental model. Apart from its efficiency the advantages with this system are the ease of handling and its high biocompatibility due to the lack of contact with circulating blood.

Download Full-text